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Abstract
Background: Even after successful detoxification, 20-40% of subjects presenting chronic migraine with symptomatic
medication overuse (CMwMO) relapse into medication overuse within one year. In this restrospective analysis on
subjects referred to our center for detoxification, we investigated whether personality traits, dependency-like
behaviors and pain coping styles predicted those who relapsed into medication overuse within the 12 months
following the detoxification and those who did not.
Methods: 63 patients with CMwMO were assessed for personality traits, mood and anxiety, pain coping styles and
dependency-like behaviors prior-to and one year after a detoxification program.
Results: Of the 42 subjects who attended 1-year follow-up interviews, 11 relapsed into medication overuse despite
a temporary benefit from detoxification and did not show clinical or psychological improvement, instead reporting
increased anxiety and unmodified perpetuation of severe dependency-like behaviors. In contrast, subjects who did
not relapse into medication overuse had clinical improvements that generalized to untreated domains, including
decreased depressive symptoms and dependency-like behaviors, although showing unmodified low internal control
over pain.
Conclusions: Subjects who did not fall into medication overuse throughout the 12 months following the
detoxification showed improved clinical, affective and dependence-related outcomes, but not pain coping
strategies. Conversely, subjects who relapsed within one year into CMwMO continued to experience significant
disability, pain intensity, and dependency-like behaviors. We believe that the persistence of maladaptive pain coping
strategies and residual symptomatology increase the risk for recurrent relapses, against which pharmacological
interventions are only partially effective. Further studies investigating predictors of relapse are needed to inform
multi-disciplinary interventions for CMwMO.
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Background
Of the subjects with headaches referred to tertiary care
clinics, as many as 15-30% are affected with chronic mi-
graine with symptomatic medication overuse (CMwMO)
[1]. Coping with the pain and disability associated with
chronic migraine (CM) is likely to be a potential cause
for increased medication intake [2,3]. However, some
subjects with CM lose control over the use of symp-
tomatic medications and develop counterproductive
behaviors, including decision making deficits that
compromise social functioning and negatively impact
the quality of life [4-6]. The underlying pathophysi-
ology of CMwMO is poorly understood. Evidence from
recent studies suggests that neurobiological factors yet
to be identified, including aberrant resting state func-
tional connectivity within the default-mode network
and reduced gray matter volumes of frontal regions,
precuneus and hippocampus, could predispose certain
subjects with CM to fall and recurrently relapse into
CMwMO [7,8]. Currently, the initial line of treatment
for CMwMO is detoxification from the offending drug
[9]. Nonetheless, studies conducted in tertiary care
clinics with patient populations and detoxification pro-
tocols similar to ours indicated that 20-40% of those
subjects who discontinue medication overuse after a
successful detoxification relapse into it within a period
of months or years [10]. Longitudinal studies investi-
gating variables associated with relapse following a
successful detoxification have produced inconclusive
result. Although the characteristics of CMwMO are
considered to be outcome predictors associated with
relapse [11,12], longitudinal studies showed that nei-
ther the frequency nor the intensity of migraines is sig-
nificantly associated with relapse rates [10], instead
suggesting that psychological and affective characteris-
tics could play a key role. Mood disorders including
depression have been considered relapse-predicting
factors [13]: a 4-year follow-up study conducted by
Hagen et al. found that lower scores for depressive
symptoms at baseline were the only factor associated
with functional improvement [14]. Furthemore, dys-
functional personality traits have been related to wors-
ened long-term prognosis in subjects with CM, and
might facilitate the perpetuation of medication con-
sumption [15,16]. Third, the severity of dependency-like
behaviors could dampen the benefits of detoxification
and increase risk to fall into CMwMO [17]. Finally, dif-
ferences in attributing control over pain to particular in-
fluence the effectiveness of therapeutic interventions
[18]. Thus, subjects with CMwMO who tend to attribute
control over pain to internal sources are more likely to ra-
tionalize painful perceptions as less-frequent, less-intense,
and less-distressing. Subjects who attribute pain control to
external domains, such as fate, luck, or medical treatment,
are conversely more likely to show maladaptive coping
strategies leading to greater functional impairment
[19,20]. We previously conducted an observational single-
arm study on subjects with CMwMO referred to our
headache center for a detoxification program. When
looking at migraine characteristics and related disability
prior-to, and then 1-year-after detoxification, we found
that detoxification was associated with significant im-
provements in the group taken as a whole [21]. In this
retrospective analysis, we decided to study compara-
tively those who did not fall into medication overuse
throughout the 12 months following the detoxification
and those who relapsed into CMwMO. In addition, we
aimed to characterize personality traits, dependency-like
behaviors and pain coping styles in the two subgroups
and to determine whether these factors could be possible
predictors of relapse into CMwMO.
Methods
63 subjects with CMwMO were consecutively recruited at
the Headache Center of the Foundation IRCCS Neurological
Institute Carlo Besta in Milan. Subjects gave informed
consent before participating and were informed of the
absence of compensation. The study was approved by
the IRCCS Neurological Institute Carlo Besta Ethics
Committee. Inclusion criteria were: (i) diagnosis of chronic
migraine, i.e. migraine headaches present on ≥ 15 days in a
month on a regular basis for > 3 months, according to the
current criteria reported in the International Classification
of Headache Disorders, 2nd Edition, and (ii) diagnosis
of medicatio overuse, i.e. intake of simple analgesic
on ≥ 15 days per month; or of any combination of ergota-
mine, triptans, analgesics, and/or opioids on ≥ 10 days per
month on a regular basis for > 3 months [22]. Exclusion
criteria were the following: other chronic pain conditions,
pregnancy, progressive neurological disorders, present or
past psychotic disorders, present or past substance and
alcohol use disorders, and use of anti-psychotic drugs in
the last 6 months. Prior to commencing the detoxification
program, subjects underwent a battery of neuropsychiatric
structured interviews and questionnaires. The detoxifica-
tion program consisted of the following: (1) intravenous
hydration for a period of 5 days; (2) intravenous steroids
for the first 5 days followed by oral prescription for an-
other 5 days; (3) diazepam orally in 2 prescriptions per
day; and (4) ev- or im-metoclopramide or indomethacine
when needed for intense rebound headache. On day 6, in
consideration of their clinical features, medical history,
and comorbidities, subjects could be prescribed with
one or more prophylactic anti-migraine compounds
recommended by published guidelines: flunarizine, pizotifen,
propranolol, or amitriptyline [23]. At the conclusion of
the detoxification program, subjects underwent a 3-hour
psychoeducational training focusing on the correct
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management of NSAIDs and triptans during migraine
episodes; additionally, they were encouraged to keep
track of medications using a headache diary. 1 year
after detoxification, the baseline assessment battery
was repeated and subjects were categorized into two
groups: Group 1 included those who did not fall into
medication overuse throughout the 12 months follow-
ing the detoxification; Group 2 included those who re-
lapsed into CMwMO.
Preliminary findings from this sample regarding clinical
improvements associated with detoxification were recently
published [21]. For the purpose of this retrospective
analysis, we focused on the following battery of assess-
ments. The Migraine Disability Assessment Questionnaire
(MIDAS) measures headache-related disability over
the past 3 months by asking 5 questions about work,
household- and social-related disability, the frequency
of headaches, and the intensity of headache pain on a
visual analog scale (VAS) [24]. The Structured Clinical
Interviews for DSM-IV-TR (SCID) Axis I Mood Disorders
and Axis II Personality Disorders assesses mood and
personality disorders, 2002). The Hamilton Rating Scales
for Anxiety and Depression (HAM-A, HAM-D) measure
the intensity of depression and anxiety symptoms [25,26].
The Pain Locus of Control Scale (PLOC) measures the
sense of perceived control over pain and health-related
outcomes [18]. The PLOC Internal subscale measures the
degree to which the individual perceives control over pain
as internal, while the PLOC Chance and Powerful Others
sub-scales are associated with strategies which attribute
control over pain to either fate and luck or to health care
providers. The Severity of Dependence Scale (SDS) identi-
fies patterns of medication overuse and dependency-like
behaviors among subjects with chronic headaches [17]. The
Structured Clinical Interview for Substance Use Spectrum
(SCI-SUBS) explores symptoms, behaviors, and experi-
ences related to several domains, including substance
use (including the use of rewarding substances), sensitivity
to substances (including mood changes, anxiety attacks,
and strange sensations), use of substances to alleviate
mood or anxiety symptoms, tendencies toward strong
emotions, and regulation of concentration at work [27].
For statistical analyses, we used the Statistical Package for
the Social Sciences (SPSS, version 17.0; Chicago, IL, USA).
We applied the Kolmogorov–Smirnov test to assess
normality: clinical and psychopathological data were
normally distributed. Due to the lack of significance in
Levene’s test, continuous data were expressed by mean
and standard deviation (M± SD). We referred to levels of
significance of p-value < 0.05. All tests were two-tailed.
We used t-tests for paired samples separately in Groups 1
and 2 to identify any improvements in clinical and psy-
chological measurements. We performed a binary logistic
regression analysis to identify differences between Groups
1 and 2 at 1-year follow-up. In order to study risk factors
for relapse into MO, we performed a series of binary
logistic regression analyses for quantitative variables
and a series of chi-squared tests for binary variables.
Baseline variables used for these analyses included: gender,
age, years with migraine, years with MO, frequency of
headaches per month, number of tablets per month,
intensity of headache pain, MIDAS total score, past
history of psychiatric disorder, psychiatric diagnosis at time
of evaluation, HAM-A and HAM-D scores, SDS score, and
SCI-SUBS total score. In addition, we aimed to perform a
logistic regression analysis based on the forward likelihood
ratio method to estimate the strength of the associations
between risk factors assessed at baseline and relapse
into CMwMO at 1-year follow-up. Finally, we compared
differences between pre- and-post-treatment PLOC scores
using a t-test for paired samples, hypothesizing that detoxi-
fication would lead to increased perceptions of internal
control over and decreased perceived external control.
Results
Our sample comprised 63 subjects (81.0% female), with
a mean age of 42.1 ± 10.2 years, and was characterized
by a long history of migraine (years with migraine:
23.3 ± 13.1, range 1–60 years) and medication overuse
(years with overuse: 2.8 ± 6.9, range 3 months-36 years).
The intensity of headache pain, the frequency of headaches
and medication intake were consistent extremely high rates
of headache-related disability and severe dependency-like
behaviors (SDS score: 8.7 ± 2.2; the cut off for SDS
medication dependence is 5). See Table 1 for additional
information. 21 subjects (38.7%) reported a past history of
mood or anxiety disorder. 18 subjects (29%) were diagnosed
with an anxiety or depressive disorder at baseline according
to SCID-I criteria. We found no significant differences
in clinical and psychological measurements between
those who had been previously diagnosed with an anx-
iety or depressive disorder and those who had not. No
subjects met the DSM-IV-TR criteria for personality
disorders. The most-used symptomatic medications for
migraine attacks were NSAIDs, triptans, or a variable
combination of both. 20 subjects (31.7%) overused triptans,
while 32 (50.8%) overused NSAIDs. The 9 remaining
subjects (14.3%) who used both types of medication
could not be further sub-classified. The analysis of variance
according to the medication type did not show significant
differences for clinical and psychological measurements.
At baseline, 28 subjects (44.4%) were not receiving pre-
ventive treatment, and 35 subjects (55.6%) had previously
been prescribed either single-compound or combination
prophylaxis. After discharge, 31 subjects (49.2%) were
newly prescribed with prophylactic medications. Within
the one year following detoxification treatment, 31 subjects
(49.2%, 25 females; age 41.1 ± 9.4) did not relapse into
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CMwMO and presented with an episodic migraine pattern
(Group 1) [22], while 11 subjects (17.5%, 8 females; age
46.6 ± 10.1) relapsed into CMwMO despite a temporary
cessation of overuse (Group 2). 21 subjects (33.3%) did
not complete 1-year follow-up assessments (18 females;
age: 41.2 ± 11.1). We were able to retrieve information
about 17 of these subjects: 3 were refractory to treatment
and required hospitalization, 4 fell into the exclusion cri-
teria for either pregnancy (2) or a suicide attempt (2), and
10 did not to return to the clinic and declined to provide
their clinical status by phone. The remaining 4 subjects did
not attend their scheduled follow-up visit. A t-test for inde-
pendent samples showed that there were no significant dif-
ferences in measurements between subjects who completed
the study and those who did attend their scheduled follow-
up visit. In total, longitudinal analyses were carried out for
42 subjects (66.7%). Table 2A shows changes among clinical
and psychological variables in Groups 1 and 2. One year
following treatment, Group 1 subjects showed significant
improvements in several domains, including frequency
of headaches per month, number of tablets per month,
MIDAS total score, intensity of headache pain, intensity
of dependency-like behaviors and depressive symptoms.
Conversely, Group 2 subjects did not show any clinical
or psychological improvement and were significantly more
anxious. Furthermore, dependency-like behaviors among
Group 2 subjects were unmodified relative to baseline.
Table 2B shows results of the logistic regression analysis:
one year following treatment, subjects in Group 1 showed
decreased tablet intake (p = 0.000), headache frequency
(p = 0.000), headache-related disability (p = 0.024), anxiety
(p = 0.024), depression (p = 0.027), and dependence-like
behaviors (p = 0.000) compared to those in Group 2. To
identify risk factors of relapse into CMwMO, a series of
binary logistic regressions and chi-square tests was
performed. However, none of the baseline clinical and
psychological measurements were associated predicted
relapse into CMwMO. Accordingly, no subsequent regres-
sion model could be built.
Regarding the pain locus of control, the sample popu-
lation (n = 63) exhibited an unbalanced PLOC profile at
baseline with a significant predominance of the Powerful
Others subscale over the Internal and Chance subscales.
We found subjects’ migraine history to be significantly
correlated with PLOC measurements as follows: the longer
the history of migraine, the lower the internal control over
pain (R = −0.326, p = 0.01), the lower the confidence in
powerful others (R = −0.352, p = 0.01), and the higher
Table 1 Baseline and 1-year follow-up characteristics for study completers and drop-outs
Enrolled (N = 63)
baseline
Dropouts (N = 21)
baseline
COmpleters
(N = 42) baseline
Completers (N = 42)
1 year follow-up
Days with headaches per month 22.2 (6.5) 23.1 (6.9) 21.7 (6.4) 11.2 (7.4)
Tablets per month 33.0 (23.2) 38.8 (25.1) 30.1 (21.9) 15.0 (16.6)
MIDAS total score 68.9 (49.9) 79.0 (58.3) 68.8 (45.0) 38.6 (38.9)
Intensity of headache on VAS 7.7 (1.6) 8.1 (1.4) 7.6 (1.7) 6.5 (1.7)
HAM-A Score 12.8 (7.6) 13.3 (8.8) 12.6 (7.1) 11.6 (6.9)
HAM-D Score 12.4 (7.2) 12.4 (7.1) 12.4 (7.4) 9.8 (5.9)
SDS Score 8.6 (2.2) 8.8 (2.3) 8.6 (2.1) 5.7 (3.2)
SCI-SUBS total score 12.2 (9.1) 11.1 (7.5) 5.6 (3.3) 7.9 (7.9)
Values expressed as Mean (SD).
Table 2 Clinical and psychological changes in Groups 1 and 2 (A) and between group differences at 1-year follow-up (B)
Table A Table B
Group 1 (n = 31) Group 2 (n = 11)
Baseline 1-year follow-up t-test (p) Baseline 1-year follow-up t-test (p) Logistic regression (p)
Days with headaches per month 21.87 (6.3) 8.3 (5.5) .000 21.4 (7.0) 19.3 (6.0) .416 .000
Tablets per month 28.39 (19.7) 7.8 (4.4) .000 34.7 (27.8) 35.5 (21.2) .940 .000
MIDAS total score 63.6 (48.7) 30.3 (26.1) .001 64.5 (34.5) 62.1 (57.8) .907 .024
Intensity of headache pain on VAS 7.6 (1.8) 6.3 (1.7) .001 7.3 (1.6) 7.1 (1.6) .676 .216
HAM-A score 13.3 (7.6) 10.2 (5.9) .014 10.5 (5.6) 15.5 (8.1) .048 .024
HAM-D score 13.2 (7.9) 8.8 (5.5) .001 10.1 (5.3) 12.6 (6.5) .133 .037
SDS score 8.3 (2.2) 4.3 (2.4) .000 9.3 (2.0) 9.4 (2.1) .911 .000
SCI-SUBS total score 10.9 (7.2) 5.6 (3.3) .000 14.6 (12.5) 7.9 (7.9) .008 .191
Values expressed as Mean (SD).
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the trust in chance (R = +0.307, p = 0.02). One year fol-
lowing treatment (see Table 3), study completers as a
whole (n = 42) did not report increased internal control
over pain, were still externally-oriented to powerful
others, and showed a less-fatalistic approach to pain
control. No significant differences between PLOC sub-
scales were observed between Groups 1 and 2 either at
baseline or at 1-year follow-up.
Discussion
The recurrence of medication overuse that often ac-
companies the chronification of migraine is a critical
factor in determining long-term functional impairment
[28]. In this study, we first aimed to characterize the
functional improvements resulting from a detoxification
program among a highly-impaired sample of subjects
presenting CMwMO and, second, to identify variables
which can predict relapse into medication overuse fol-
lowing an effective detoxification treatment. Our sample
was characterized by severe migraine features including:
high frequency and intensity of migraine episodes, high
medication intake, significant anxiety and depression
levels, and dysfunctional dependency-like behaviors and
pain coping skills.
The 1-year relapse rate for our sample was approximately
in line with other studies [10-12]. Notably, within the
group of subjects who discontinued medication over-
use and presented at 1-year follow-up with episodic
migraine, significant improvements generalized from
migraine characteristics to untreated domains, including
decreased depressive symptoms, headache related disability,
and dependency-like behaviors [13]. In contrast, sub-
jects who relapsed into CMwMO did not show clinical
or psychological improvements, instead reporting increased
anxiety and unmodified perpetuation of severe dependency-
like behaviors. Furthermore, none of the baseline measure-
ments predicted relapse into CMwMO.
We were particularly interested in assessing the PLOC
among our sample. In line with previous studies on
subjects with chronic pain [18], we found that, before
the detoxification, the longer the history of CMwMO
the lower are the perceived control over pain and the
confidence in physicians’ pain management treatments.
Increases in perceptions of internal pain control and
decreases in perceptions of external pain control are both
associated with successful completion of detoxification
treatment and psychoeducation [19]. Unfortunately, our
subjects showed unmodified low perceived control over
pain and persisted in attributing it to powerful others
and chance, irrespective of relapse into CMwMO. These
findings suggest that detoxification and psychoeducation
were not able to influence positively pain coping strategies
among our sample.
Several limitations must be considered when interpreting
the findings from this study. First, we acknowledge that
the sample size at study completion did not allow suffi-
cient power to detect effect sizes. Second, the high at-
trition rate can also account for the limited validity of
these preliminary findings. Based on our prior experience
recruiting subjects with CMwMO without any compensa-
tion [23], we approached our study design with a conser-
vative estimate for drop-out rate of 20%. We believe that
the severity of functional impairment associated with
CMwMO and the intrinsic difficulty of conducting co-
hort studies without any compensation, people with a
severe low-prevalence disorder are elements that strongly
influenced attrition and sample size. Although we were
inclined to believe that subjects who dropped out of the
study had worse clinical and affective profiles, analysis
of baseline differences between Groups 1 and 2 yielded
no significant results.
In this retrospective analysis, we were not able to de-
termine clinical and psychological predictors of relapse
into CMwMO. Nonetheless, we believe that longer
treatment trials in larger samples of patients with CM
should be conducted to identify clusters of responders
to detoxification protocols and to study biopsychological
markers and neuroendophenotypes of recurrent relapses
into medication overuse. In particular, emerging evidence
supports the hypothesis that functional alterations of the
default-mode network are associated with the perpetuation
of counterproductive dependency-like behaviors, which are
know to impair the clinical course of migraine [4,7].
Additional factors should be taken into consideration
when identifying predictors of relapse within this patient
population. First, the superimposition of medication
overuse on CM complicates subjects’ clinical status to
the extent that it might no longer be possible to segre-
gate independent risk factors. The predictive value of
the variables we collected may have been confounded
by the reciprocal influences among the determinants of
functional impairment. Furthermore, the lack of signifi-
cant results could be attributed to the great variability
among medication protocols targeting the complex re-
sidual clinical symptoms and psychiatric comorbidities
among subjects with CMwMO. Although this variability
complicates statistical pharmacological analyses, we believe
that effective interventions for CMwMO must offer an
Table 3 Changes in pain locus of control for study
completers
Pre-treatment
(N = 42)
Post-treatment
(N = 42)
t-test
t (p)
PLOC internal 37.5 (10.7) 39.1 (11.1) 0.306 (−1.037)
PLOC powerful others 48.1 (10.2) 46.7 (9.6) 0.451 (0.762)
PLOC chance 35.5 (10.7) 29.2 (6.5) 0.000 (5.322)
Values expressed as Mean (SD).
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individually-tailored and multi-disciplinary approach
that targets the residual clinical symptoms or psychi-
atric comorbidities and incorporates both symptomatic
and prophylactic polytherapies, and psychotherapeutic
approaches [29,30].
Conclusion
Despite the aforementioned limitations, findings of this
exploratory study support the use of detoxification and
psychoeducation to improve clinical, affective, and func-
tional outcomes in a subgroup of subjects with CMwMO.
However, these interventions appear to be ineffective in
another subgroup of subjects, who continue to experience
significant headache-related disability, pain intensity, and
dependency-like behaviors. We believe that the persist-
ence of maladaptive pain coping strategies and residual
symptomatology increase the risk for recurrent relapses,
against which pharmacological interventions are only
partially effective. Further studies investigating predic-
tors of relapse are needed to inform multi-disciplinary
interventions for CMwMO.
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